ReviewSignal transduction and targeted therapy2026
Esophageal cancer: from pathogenesis to precision therapies.
Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- FANCI promotes esophageal squamous cell carcinoma progression and cell cycle regulation and interacts with FANCD2.Journal of gastrointestinal oncology · 2026Article
- Single-cell and machine learning identify a trihydroxybutyrylation-related prognostic signature in esophageal cancer.Journal of thoracic disease · 2026Article
- Bone marrow mesenchymal stem cell-derived exosomal miR-93-5p suppresses esophageal squamous cell carcinoma progression and immune escape through targeting PD-L1.Translational cancer research · 2026Article
- Inhibition of the AT-Hook DNA-Binding Domain Attenuates HMGA2-Mediated Epithelial Mesenchyme Transition in Esophageal Cancer Cells.International journal of molecular sciences · 2026Article
- Development and validation of a clinically interpretable risk scoring system for predicting one-year all-cause mortality in esophageal cancer: a population-based study.Journal of thoracic disease · 2026Article
- ASAP3 activates the NF-κB signaling pathway to promote the progression of esophageal squamous cell carcinoma.Discover oncology · 2026Article
- Immunosuppressive tumor microenvironment and immunotherapy resistance of esophageal carcinoma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Esophageal cancer (EC), encompassing primarily esophageal squamous-cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), continues to pose a significant global health burden, which is largely due to delayed diagnosis and limited therapeutic efficacy. In this review, we synthesize current insights into key aspects of EC, including established risk factors, the stepwise process of tumorigenesis, strategies for early detection and prevention, and emerging therapeutic approaches. Emphasis is particularly placed on the molecular underpinnings of (1) early tumor initiation and malignant progression, with a focus on genetic mutations, epigenetic modifications, and alterations within the tumor microenvironment; (2) the clonal expansion and metabolic reprogramming that play essential roles in shaping the evolutionary trajectory of esophageal cancer, thereby promoting intratumoral heterogeneity; (3) the transition from normal epithelium to invasive carcinoma in both ESCC and EAC driven by sequential disruptions of molecular networks governing epithelial homeostasis; and (4) advances in early screening techniques and minimally invasive interventions that may offer new opportunities for EC prevention and early detection, especially in high-risk populations. In addition, we summarize recent progress in precision treatment, including chemotherapy, targeted therapy, immunotherapy, and multidisciplinary treatment. By delineating the molecular and cellular mechanisms underlying EC initiation and progression, this review aims to inform future directions in early diagnosis, risk stratification, and individualized therapy, ultimately contributing to improved clinical outcomes and precision prevention of EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.